Preclinical Results

EIP Pharma has conducted neflamapimod preclinical studies in animal models. In these models, neflamapimod improved neurological outcomes, supporting its use to treat neurological disorders in human patients.

In aged rats with identified cognitive deficit, neflamapimod improved cognitive performance (p=0.007), as assessed in a maze test. The aged rat model was chosen to evaluate neflamapimod because the cognitive deficits in that model are due to inflammation-induced synaptic dysfunction.

View the Publication

Neflamapimod was also studied in a rat stroke model. Neflamapimod administered for a duration of six weeks after the stroke led to multiple improved parameters of neurologic function compared to control (p < 0.001 for each of global neurologic scores, motor- and sensory-specific tests). Recovery after stroke is largely dependent on neuronal and synaptic plasticity, thus these results support our hypothesis that neflamapimod can reverse synaptic damage.

View the Abstract

EIP Pharma Clinical Milestone Pipeline

See the milestones reached and the clinical trial timetable for each of EIP Pharma’s areas of focus.


"Neflamapimod treatment showed improvement in memory tests that assess immediate and delayed recall in two phase 2a studies, strongly suggestive of reversal of synaptic dysfunction. With the demonstration of proof-of-mechanism and the definition of an optimal dose, neflamapimod is well positioned to demonstrate proof-of-concept on clinical cognitive endpoints in a subsequent study in patients with early Alzheimer's disease."

Professor Philip Scheltens, principal investigator for Study 302 and Director of the Alzheimers Centre at the VU Medical Center